Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Rises By 25.5%

Pulmatrix, Inc. (NASDAQ:PULM) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 6,400 shares, a growth of 25.5% from the August 31st total of 5,100 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 12,200 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Pulmatrix in a research note on Monday, September 23rd. They set a “hold” rating on the stock.

Pulmatrix Trading Up 5.4 %

Pulmatrix stock opened at $2.14 on Monday. The company has a fifty day simple moving average of $2.10 and a 200-day simple moving average of $1.98. The stock has a market cap of $7.81 million, a P/E ratio of -0.89 and a beta of 0.99. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $2.75.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The business had revenue of $1.55 million for the quarter.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.